Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
25%
Ph not_applicable
1
25%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(2)

Detailed Status

Recruiting2
Completed2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 11 (50.0%)
N/A1 (50.0%)

Trials by Status

recruiting250%
completed250%

Recent Activity

2 active trials
Showing 4 of 4
recruiting

Microglia Activation in Asthma

NCT04307667
completed

Microglial Activation in Inflammatory Bowel Disease

NCT03487926
recruitingnot_applicable

Molecular Neuroimaging of Neuroinflammation in Neurodegenerative Dementias

NCT02945774
completedphase_1

Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions

NCT00970333

Clinical Trials (4)

Showing 4 of 4 trials
NCT04307667

Microglia Activation in Asthma

Recruiting
NCT03487926

Microglial Activation in Inflammatory Bowel Disease

Completed
NCT02945774Not Applicable

Molecular Neuroimaging of Neuroinflammation in Neurodegenerative Dementias

Recruiting
NCT00970333Phase 1

Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions

Completed

All 4 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
4